Group 1 - Cambridge Technology plans to invest 400 million yuan to establish a fund focused on optical devices and chips, aiming to invest in early-stage and growth-stage companies in the hard technology sector [1] - Tunnel Corporation's consortium won a bid for a highway project in Henan with a total investment of 6.49 billion yuan, using a BOT model for a 33.25-year cooperation period [2] - Hongrun Construction won a bid for a project worth 230 million yuan, which represents 3.88% of the company's projected revenue for 2024 [3] Group 2 - Tongrentang's product, Canling Baizhu Powder, received product registration approval from Health Canada, aimed at treating symptoms related to spleen and stomach weakness [4] - Hunan Baiyin announced a scheduled annual maintenance from December 9, 2025, to January 5, 2026, for equipment and facilities [5] - Changchun Gaoxin's subsidiary had two drugs included in the national medical insurance catalog for 2025 [6] Group 3 - Dongfang Securities' chairman resigned due to work relocation [7] - Xuantai Pharmaceutical's product, Sitagliptin Metformin Sustained-Release Tablets, was renewed for inclusion in the national medical insurance catalog [8] - ST Weihai was pre-selected for a smart agriculture EPC project with a bid of 652 million yuan, accounting for 26.27% of the company's projected revenue for 2024 [9] Group 4 - Guoxin Technology successfully tested an anti-quantum password financial POS chip, supporting both traditional and quantum-resistant algorithms [10] - Huaren Health's subsidiary received acceptance for a drug registration application for Lactulose Oral Solution, a common laxative [11] - Ankai Bus reported a 57.71% year-on-year increase in sales for the first 11 months of the year [12] Group 5 - Zhongyan Dadi's subsidiary won a bid for a project worth 73.86 million yuan [13] - Zhejiang Rongtai plans to invest 77 million USD in a factory in Thailand, focusing on mica paper and robot components production [14] - Optoelectronics plans to use up to 450 million yuan of idle funds for cash management [15] Group 6 - Tianyu Biological reported a 45.15% year-on-year decline in sales revenue from pig sales in November [16] - Daqin Railway's cargo transport volume increased by 1.75% year-on-year in November [17] - Yabo Co. won a bid for a heavy truck charging station project worth 3.616 million yuan [18] Group 7 - Hongri Pharmaceutical's product continues to be included in the national medical insurance catalog [19] - Jinggong Steel Structure signed a contract for steel structure installation worth approximately 470 million yuan for an overseas project [20] - Xizang Pharmaceutical's product, Xinhuasuan, continues to be included in the national medical insurance catalog [21] Group 8 - Guangdong Electric Power A announced the successful commissioning of a 1000MW unit at the Maoming Boge Power Plant [22] - Fuan Pharmaceutical's product, Palivizumab Injection, was newly included in the national medical insurance catalog [23] - Lizhu Group reported that 194 products were included in the 2025 national medical insurance catalog [24] Group 9 - Haisan Pharmaceutical's injection of Lantanol was included in the national medical insurance catalog [25] - Zhongtong Bus reported a 39.53% year-on-year increase in sales volume in November [26] - Shaanxi Coal Industry reported a 6.03% year-on-year increase in coal production in November [27] Group 10 - Haooubo's subsidiary received a medical device registration certificate for an IgG4 testing kit [28] - Yaopi Glass plans to invest 690 million yuan in new automotive glass production lines [30] - Huadian International completed the issuance of 2 billion yuan in medium-term notes [31] Group 11 - Zhongzai Zihuan's subsidiary won a bid for a green recycling project worth 205 million yuan [32] - Dabeinong reported a 25.26% year-on-year decline in sales revenue from pig sales in November [33] - Xiangjia Co. reported a 3.77% year-on-year increase in live poultry sales revenue in November [34] Group 12 - Huanxu Electronics reported a consolidated revenue of 5.198 billion yuan in November, a decrease of 3.34% year-on-year [35] - Aonong Biological reported a 72.21% year-on-year increase in pig sales volume in November [36] - Samsung Medical's subsidiary was pre-selected for a procurement project worth approximately 108 million yuan [37]

Core Viewpoint - Tongrentang has received approval from the Canadian Ministry of Health for its product, Shenling Baizhu San, which is now registered in Canada for specific health indications [1] Company Summary - Tongrentang's subsidiary, Beijing Tongrentang Co., Ltd., has been granted a Class III Product License by the Canadian Ministry of Health [1] - The product Shenling Baizhu San is indicated for alleviating symptoms related to spleen and stomach weakness, including reduced appetite, loose stools, shortness of breath, cough, and fatigue [1]

Core Viewpoint - Tong Ren Tang (600085.SH) has received approval from the Canadian Ministry of Health for its product license, allowing its product Shen Ling Bai Zhu San to be registered in Canada [1] Group 1 - The announcement highlights that the Beijing Tong Ren Tang Pharmaceutical Factory, a branch of Tong Ren Tang, has successfully obtained a Class III product license [1] - The approval signifies an important step for the company in expanding its market presence in Canada [1]

Core Viewpoint - Tong Ren Tang (600085.SH) has received approval from the Canadian Ministry of Health for a Class III Product License, allowing its product Shen Ling Bai Zhu San to be registered in Canada [1] Group 1 - The announcement highlights the successful registration of Shen Ling Bai Zhu San, indicating the company's expansion into the Canadian market [1] - This approval reflects the company's commitment to international growth and the increasing recognition of traditional Chinese medicine products [1]

北京同仁堂股份有限公司（以下简称公司）分支机构北京同仁堂股份有限公 司同仁堂制药厂（以下简称同仁堂制药厂）收到加拿大卫生部核准签发的《产品 许可证（三类）》，同仁堂制药厂产品参苓白术散获得加拿大产品注册。公司现将 有关情况公告如下： 一、 产品注册许可基本情况 产品名称：参苓白术散 产品剂型：散剂 品种批准文号：80143529 持证商名称：北京同仁堂股份有限公司同仁堂制药厂 证券代码：600085 证券简称：同仁堂 公告编号：2025-040 北京同仁堂股份有限公司 关于获得加拿大产品许可证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 在境外销售产品容易受到境外政策环境变化、市场推广、客户认可、市场竞 争等多种因素影响，敬请广大投资者谨慎决策，注意投资风险。 特此公告。 北京同仁堂股份有限公司董事会 2025 年 12 月 9 日 持证商地址：北京市大兴区中关村科技园区大兴生物医药产业基地天贵大街 33 号 产品适应症：基于传统中医药理论的药物/产品/制剂；用于缓解脾胃虚弱， 症见食少便溏，并能缓解气短，咳嗽，肢倦 ...

Core Viewpoint - Tong Ren Tang (600085.SH) has received approval from Health Canada for its product Shen Ling Bai Zhu San, marking a significant step in its international expansion efforts [1][2] Group 1: Product Approval - The product Shen Ling Bai Zhu San has been granted a Class III product license by Health Canada, indicating its compliance with Canadian regulations [1] - The product is based on traditional Chinese medicine principles and is indicated for alleviating symptoms related to spleen and stomach weakness, such as reduced appetite and loose stools, as well as for relieving shortness of breath, cough, and fatigue [1] Group 2: Research and Development Investment - As of the date of the announcement, the cumulative investment in the research and development of the product amounts to approximately 2.29 million yuan, which is unaudited [2]

Core Viewpoint - Tong Ren Tang (600085) has received approval from the Canadian Ministry of Health for its product, Shen Ling Bai Zhu San, which is now registered in Canada for use in traditional Chinese medicine [1] Group 1: Company Developments - Tong Ren Tang's subsidiary, Tong Ren Tang Pharmaceutical Factory, has been granted a Class III Product License by the Canadian Ministry of Health [1] - The product Shen Ling Bai Zhu San is indicated for alleviating symptoms related to spleen and stomach weakness, including reduced appetite and loose stools, as well as for relieving shortness of breath, cough, and fatigue [1] Group 2: Product Information - Shen Ling Bai Zhu San is based on traditional Chinese medicine principles and is used to tonify the spleen and stomach while benefiting lung qi [1]

Core Viewpoint - Tong Ren Tang announced that its subsidiary, Tong Ren Tang Pharmaceutical Factory, received a product license (Class III) from Health Canada for its product Shen Ling Bai Zhu San, which is used to alleviate symptoms of spleen and stomach weakness [1] Group 1 - The product is a powder formulation aimed at addressing specific health issues [1] - The total investment in the product's research and development has reached approximately 2.29 million yuan [1] - The product must still undergo Canadian production quality system certification and other approvals before it can be sold in Canada, indicating uncertainty in the commercialization process [1] Group 2 - The approval of the product is not expected to have a significant impact on the company's recent operating performance [1]

2025.12.07 本文字数：1371，阅读时长大约3分钟 作者 |第一财经钱童心 近日，第一财经记者注意到网上有不少消费者抱怨为了买老字号中药品牌"北京同仁堂"的产品，在网上选了又选，但最后还是买到了"假的同仁堂"—— 没有"双龙标"。 为此，记者从互联网电商平台上搜索"北京同仁堂"发现，确实存在多个"北京同仁堂"商标，例如北京同仁堂兴安保健拥有的"内廷上用"相关商标，以及 北京同仁堂（四川）药业拥有的"朕皇"相关商标。 公开信息显示，北京同仁堂兴安保健、北京同仁堂（四川）药业均为北京同仁堂集团的下属公司。2024年8月，同仁堂集团曾发布声明称"从未允许下属 公司使用'同仁堂'商标、字号及任何含有'北京同仁堂''同仁堂'字样的标识，对外开展招商加盟活动，该类合作、加盟、宣传、销售行为均与我公司无 关。"今年9月，该集团又提到其依法享有"同仁堂双龙商标"的注册商标专用权，任何未经授权擅自使用的行为均属于侵权行为。 对此，上海大邦律师事务所合伙人游云庭对第一财经记者表示："北京同仁堂下属公司使用其自有商标，委托生产商或授权第三方生产药品时，虽然号 称使用的是内廷上用，朕皇等商标，但这些产品显著位置均有其公司全 ...

2025.12. 07 本文字数：1371，阅读时长大约3分钟 作者 | 第一财经 钱童心 近日，第一财经记者注意到网上有不少消费者抱怨为了买老字号中药品牌"北京同仁堂"的产品，在 网上选了又选，但最后还是买到了"假的同仁堂"——没有"双龙标"。 对此，上海大邦律师事务所合伙人游云庭对第一财经记者表示："北京同仁堂下属公司使用其自有商 标，委托生产商或授权第三方生产药品时，虽然号称使用的是内廷上用，朕皇等商标，但这些产品显 著位置均有其公司全称，但其中 ' 北京同仁堂 ' 这几个字的字体明显和公司全称里的其他内容不一 致，消费者非常容易就可以发现北京同仁堂的字样，在商标法上，这种属于突出使用，实际上还是对 北京同仁堂进行了商标性使用。" 游云庭分析称，作为上级公司，北京同仁堂虽然对外声称对外没有贴牌，但作为医药领域的公司，不 可能不知道下属公司对外授权时产品包装对于北京同仁堂的使用方式，而这种使用方式，虽然也可以 解释为公司名称权或者字号权，但从消费者认知的角度，依然是在使用北京同仁堂的商标。 "因此，使用'内廷上用'，'朕皇'等商标的产品如果发生质量问题，或者虚假宣传问题，北京同仁堂 公司实际也是负有一定责 ...